Welcome to our dedicated page for IONIS PHARMACEUTICALS SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IONIS PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IONIS PHARMACEUTICALS's regulatory disclosures and financial reporting.
Ionis Pharmaceuticals submitted a Form 144 notifying a proposed sale of 973 shares of Common Stock (issued as RSUs under the 2011 Equity Incentive Plan) through Morgan Stanley on 04/16/2026. The filing lists prior share sales in the past three months: 8,480 shares sold on 01/15/2026 for $636,932.80 and 6,179 shares sold on 01/30/2026 for $513,047.87.
Ionis Pharmaceuticals files a Rule 144 notice to sell 5,619 shares of Common Stock. The filing lists the securities as RSUs granted under the 2011 Equity Incentive Plan with an intended sale date of 04/16/2026. The notice also reports prior open-market sales of 4,096, 5,296, and 6,907 shares on 03/03/2026, 01/30/2026, and 01/16/2026, respectively.
Ionis Pharmaceuticals director Joseph Klein III exercised stock options and sold shares on April 1, 2026. He exercised options for 12,000 shares at $38.06 and 10,321 shares at $41.08, acquiring a total of 22,321 common shares. He then sold 20,105 shares at a weighted average price of $75.503 and 2,216 shares at $75.954 in open-market transactions pursuant to a Rule 10b5-1 Trading Plan adopted on November 26, 2025. After these transactions, he held 11,014 shares directly. An additional 100 shares are held indirectly by his son, for which he disclaims beneficial ownership.
Ionis Pharmaceuticals executive Shannon L. Devers, EVP and Chief Human Resources Officer, sold 6,193 shares of Common Stock in an open-market transaction at a weighted average price of $74.0535 per share on April 2, 2026. The sale was made pursuant to a Rule 10b5-1 Trading Plan adopted on November 24, 2025. After this transaction, Devers directly holds 16,348 shares of Ionis Pharmaceuticals common stock.
IONS notice of proposed sale of 68,800 shares of Common Stock under Rule 144. The form lists a sale venue as Nasdaq and an effective/filing date of 03/03/2026. The excerpt also shows 50,432 shares from an option exercise and 18,368 RSUs with grant dates.
Ionis Pharmaceuticals Inc: The Vanguard Group filed Amendment No. 14 to a Schedule 13G/A reporting beneficial ownership in Ionis Pharmaceuticals common stock. The filing states 0 shares beneficially owned and 0% of the class, after an internal realignment of Vanguard subsidiaries.
The filing explains that on January 12, 2026 Vanguard reorganized certain subsidiaries to report separately in reliance on SEC Release No. 34-39538; the reporting entity now states no beneficial ownership in the class. The form is signed by Ashley Grim, Head of Global Fund Administration.
IONS filing amends a Form 144 reporting proposed sales of Common Stock by a selling holder. The filing lists sales dated 01/16/2026 and 01/30/2026 with reported quantities of 9,302 and 6,179 respectively. The securities are listed as Common Stock on Nasdaq.
Ionis Pharmaceuticals executive Eugene Schneider reported an open-market sale of 5,812 shares of Common Stock. The shares were sold at a weighted average price of $70.9715 per share on March 19, 2026, under a pre-arranged Rule 10b5-1 trading plan. After the transaction, Schneider directly holds 63,890 shares.
IONS affiliate filed a Form 144 to sell Common Stock. The notice lists proposed sales tied to 01/15/2026 performance stock units and a reported sale on 03/19/2026. The filing names Stifel Nicolaus & Company as broker and lists quantities including 6179 shares sold in the past three months and figure 512906.00.
Ionis Pharmaceuticals EVP, Finance & CFO Elizabeth L. Hougen reported a series of stock option exercises followed by open-market sales of common stock. On March 16, 2026, she exercised options to acquire a total of 174,999 shares of common stock at exercise prices of $32.6000, $37.5800, $56.7800 and $60.8900 per share. That same day, she sold 215,048 shares of common stock in open-market transactions at weighted average prices of $72.3810 and $72.7650 per share. On March 17, 2026, she sold an additional 10,172 shares at a weighted average price of $73.2070 per share, bringing total reported sales to 225,220 shares. The filing states these sales were made pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. Following the transactions, Hougen directly owns 82,660 shares of Ionis common stock.